Rossari Biotech buys Tristar Intermediates for ₹120 crore

Our Bureau Mumbai | Updated on July 18, 2021

Rossari Biotech, a speciality chemicals company, has acquired Tristar Intermediates for an enterprise value of ₹120 crore.

As per the agreement signed, Rossari will initially acquire 76 per cent equity and the balance stake over the next three years.

Rossari plans to fund the deal entirely through internal accruals, the company said. The blend of capabilities will add scale, provide cross-selling opportunities, and accelerate growth for Rossari, while significantly enhancing value creation in the longer term, it said.

The synergistic acquisition provides Rossari with enhanced portfolio of products, presence in new and untapped international markets and access to newer technologies.

Published on July 18, 2021

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor

You May Also Like